Miller RG - Search Results

1

A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients.

Jackson CE, Rosenfeld J, Moore DH, Bryan WW, Barohn RJ, Wrench M, Myers D, Heberlin L, King R, Smith J, Gelinas D, Miller RG. Jackson CE, et al. Among authors: miller rg. J Neurol Sci. 2001 Oct 15;191(1-2):75-8. doi: 10.1016/s0022-510x(01)00617-7. J Neurol Sci. 2001. PMID: 11676995 Clinical Trial.

2

Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group.

McGuire D, Garrison L, Armon C, Barohn R, Bryan W, Miller R, Parry G, Petajan J, Ross M. McGuire D, et al. Neurology. 1996 May;46(5):1442-4. doi: 10.1212/wnl.46.5.1442. Neurology. 1996. PMID: 8628496

3

A brief quality-of-life measure for ALS clinical trials based on a subset of items from the sickness impact profile. The Syntex-Synergen ALS/CNTF Study Group.

McGuire D, Garrison L, Armon C, Barohn RJ, Bryan WW, Miller R, Parry GJ, Petajan JH, Ross MA. McGuire D, et al. J Neurol Sci. 1997 Oct;152 Suppl 1:S18-22. doi: 10.1016/s0022-510x(97)00239-6. J Neurol Sci. 1997. PMID: 9419049

4

Quality of life for ventilator-dependent ALS patients and their caregivers.

Gelinas DF, O'Connor P, Miller RG. Gelinas DF, et al. Among authors: miller rg. J Neurol Sci. 1998 Oct;160 Suppl 1:S134-6. doi: 10.1016/s0022-510x(98)00212-3. J Neurol Sci. 1998. PMID: 9851663

5

A placebo-controlled trial of gabapentin in spinal muscular atrophy.

Miller RG, Moore DH, Dronsky V, Bradley W, Barohn R, Bryan W, Prior TW, Gelinas DF, Iannaccone S, Kissel J, Leshner R, Mendell J, Mendoza M, Russman B, Samaha F, Smith S; SMA Study Group. Miller RG, et al. J Neurol Sci. 2001 Oct 15;191(1-2):127-31. doi: 10.1016/s0022-510x(01)00632-3. J Neurol Sci. 2001. PMID: 11677003 Clinical Trial.

6

Can we eliminate placebo in ALS clinical trials?

Bryan WW, Hoagland RJ, Murphy J, Armon C, Barohn RJ, Goodpasture JC, Miller RG, Parry GJ, Petajan JH, Ross MA, Stromatt SC; rhCNTF ALS Study Group. Bryan WW, et al. Among authors: miller rg. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Apr;4(1):11-5. doi: 10.1080/14660820310006661. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003. PMID: 12745612 Clinical Trial.

7

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Miller RG, Mitchell JD, Lyon M, Moore DH. Miller RG, et al. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):191-206. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003. PMID: 13129806 Review.

8

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group.

Miller RG, Moore D, Young LA, Armon C, Barohn RJ, Bromberg MB, Bryan WW, Gelinas DF, Mendoza MC, Neville HE, Parry GJ, Petajan JH, Ravits JM, Ringel SP, Ross MA. Miller RG, et al. Neurology. 1996 Dec;47(6):1383-8. doi: 10.1212/wnl.47.6.1383. Neurology. 1996. PMID: 8960715 Clinical Trial.

9

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group.

Miller RG, Petajan JH, Bryan WW, Armon C, Barohn RJ, Goodpasture JC, Hoagland RJ, Parry GJ, Ross MA, Stromatt SC. Miller RG, et al. Ann Neurol. 1996 Feb;39(2):256-60. doi: 10.1002/ana.410390215. Ann Neurol. 1996. PMID: 8967757 Clinical Trial.

10

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Miller RG, Mitchell JD, Moore DH. Miller RG, et al. Cochrane Database Syst Rev. 2000;(2):CD001447. doi: 10.1002/14651858.CD001447. Cochrane Database Syst Rev. 2000. PMID: 10796796 Updated. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

679 results

Search Page